Neoplasms, Plasma Cell: all 2,314 studies
Page 14 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.
- Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple MyelomaTerminatedNCT03266692Phase 1
- A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03242889Phase 1
- The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)CompletedNCT03242460Phase 2
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Phase 3
- High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal ImpairmentCompletedNCT03234335
- Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCTCompletedNCT03233776Phase 2
- An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple MyelomaWithdrawnNCT03227432Phase 2
- Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)WithdrawnNCT03221634Phase 2
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Phase 3
- A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without PomalidomideCompletedNCT03215524Phase 2
- Study of Risk Factors and Genetic Association With Bortezomib-induced Peripheral Neuropathy in Multiple MyelomaStatus unknownNCT03210753
- Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT03200626
- Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRPTerminatedNCT03196947Phase 1/2
- Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple MyelomaWithdrawnNCT03191981Phase 1/2
- Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT03190525
- MUK Nine b: OPTIMUM Treatment ProtocolActive, not recruitingNCT03188172Phase 2
- Nivolumab Combined With Daratumumab With or Without Low-dose CyclophosphamideCompletedNCT03184194Phase 2
- Multiple Myeloma Patient RegistryTerminatedNCT03180853
- Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple MyelomaTerminatedNCT03173430Early Phase 1
- 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple MyelomaWithdrawnNCT03168100Phase 2
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2
- Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment LinesCompletedNCT03155100Phase 2
- CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple MyelomaStatus unknownNCT03150316Phase 1
- Diagnostic Imaging of Myeloma Bone LesionsCompletedNCT03147326Not applicable
- Prevalence of Asymptomatic Thrombosis in Multiple MyelomaWithdrawnNCT03145870Not applicable
- Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple MyelomaCompletedNCT03143985Phase 1
- Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory MyelomaStatus unknownNCT03143049Phase 3
- Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory MyelomaStatus unknownNCT03143036Phase 2
- Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT03140943Phase 2
- A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple MyelomaCompletedNCT03136653Phase 1/2
- Feasibility of Pre Transplant Exercise (Pre-habilitation) for Multiple Myeloma Patients Awaiting Autologous Stem Cell TransplantationCompletedNCT03135925Not applicable
- Expanded Access to Elotuzumab (Empliciti) for Multiple MyelomaNo longer availableNCT03126617
- cGA in Newly-diagnosed Elderly MM Patients: a Multi-center, Prospective, Non-interventional Study.Status unknownNCT03122327
- Dysregulation of Glutamine Activity in the Pathogenesis of Multiple MyelomaCompletedNCT03119883Not applicable
- Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple MyelomaCompletedNCT03111992Phase 1
- Combination Study for High Risk Multiple Myeloma PatientsTerminatedNCT03104270Phase 2
- BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple MyelomaStatus unknownNCT03093168Phase 1
- Real-world Use of Carfilzomib Among Multiple Myeloma Patients in EuropeCompletedNCT03091127
- LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple MyelomaActive, not recruitingNCT03090659Phase 1/2
- Collection of Additional Data Followed the Study IFM 2013-04Status unknownNCT03089411
- Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults With Multiple MyelomaCompletedNCT03068637Not applicable
- Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple MyelomaCompletedNCT03068351Phase 1
- CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple MyelomaStatus unknownNCT03051841Phase 1
- Improving the Quality of Multiple Myeloma Treatment With Patient Care PlansCompletedNCT03046329Not applicable
- Vaccination With PD-L1 Peptide Against Multiple MyelomaCompletedNCT03042793Phase 1
- A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple MyelomaTerminatedNCT03033316Phase 1/2
- Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple MyelomaTerminatedNCT03023527Phase 1
- Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHLCompletedNCT03019666Phase 1
- A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer IndicationsStatus unknownNCT03018405Phase 1/2
- Viral Immunotherapy in Relapsed/Refractory Multiple MyelomaStatus unknownNCT03015922Phase 1
- Mobile Health Device Study for Myeloma PatientsCompletedNCT03006315
- 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)WithdrawnNCT03003728Phase 2
- Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible PatientsCompletedNCT03001804
- 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance TherapyWithdrawnNCT03000634Phase 2
- Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization StrategiesCompletedNCT02997813
- Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple MyelomaCompletedNCT02992483Phase 1
- Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory MyelomaWithdrawnNCT02986451Phase 2
- Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple MyelomaWithdrawnNCT02985333Phase 2
- Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma PatientsStatus unknownNCT02981199Not applicable
- A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or LymphomaTerminatedNCT02978235Phase 1
- Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal ImpairmentCompletedNCT02977494Phase 2
- Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple MyelomaCompletedNCT02976493
- Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma MultipleStatus unknownNCT02976272
- Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT02971410Early Phase 1
- Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
- Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)Status unknownNCT02955810Phase 1
- A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)CompletedNCT02955550Phase 1
- Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant RecoveryCompletedNCT02955043Not applicable
- A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT02954796Phase 1
- Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of ImprovementTerminatedNCT02952573Phase 2
- Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromActive, not recruitingNCT02952508Phase 2
- A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer TreatmentWithdrawnNCT02951117Phase 1
- A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in SpainCompletedNCT02946333
- A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of UseCompletedNCT02922543
- Comparison of Geriatric Screening Methods in Newly Diagnosed Multiple Myeloma PatientsCompletedNCT02918695
- A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell TransplantationCompletedNCT02918331Phase 1
- Prevalence of Ocular Disorders in Multiple Myeloma (MM-OO-16)CompletedNCT02917239
- Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple MyelomaStatus unknownNCT02916420Phase 3
- An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical PracticeCompletedNCT02902900
- Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)Active, not recruitingNCT02899052Phase 2
- Back Pain Prevention in Multiple Myeloma Using an External Spinal BraceCompletedNCT02898064Not applicable
- Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple MyelomaTerminatedNCT02897830Phase 2
- Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance StrategyCompletedNCT02891811Phase 2
- A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MMActive, not recruitingNCT02886065Phase 1
- MMRF Molecular Profiling ProtocolActive, not recruitingNCT02884102
- Early Patient Access Treatment Use Protocol CA204-220No longer availableNCT02856438
- Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic TherapyCompletedNCT02852837Phase 1
- Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)CompletedNCT02851056Early Phase 1
- A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine ClearanceCompletedNCT02849444
- BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)CompletedNCT02834364Phase 2
- A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With MyelomaCompletedNCT02831686Phase 1
- Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT02811978Phase 3
- A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple MyelomaCompletedNCT02811822Phase 1
- Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,PanobinostatWithdrawnNCT02802163Phase 1/2
- Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.Status unknownNCT02797041
- Vinorelbine and Gemcitabine in MyelomaCompletedNCT02791373Phase 2
- Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic MyelomaTerminatedNCT02784483Phase 1
- Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple MyelomaTerminatedNCT02773550Phase 4
- A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple MyelomaTerminatedNCT02756728Phase 1/2
- Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple MyelomaWithdrawnNCT02756663Phase 2